Prof. Benjamin Solomon, Peter MacCallum Cancer Centre, Australia
Prof. Solomon discussed key considerations in resectable and advanced ALK-positive NSCLC, including risk factors that influence treatment selection, the shift toward chronic disease management in the lorlatinib era, and the impact of patient preferences on treatment sequencing and communication. He also shared his perspectives on how to achieve high-quality long-term survival and the most promising future directions in ALK research.